Glaukos Corporation (GKOS)
NYSE: GKOS · IEX Real-Time Price · USD
99.48
-0.63 (-0.63%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Glaukos Revenue
In the year 2023, Glaukos had annual revenue of $314.71M with 11.26% growth. Revenue in the quarter ending December 31, 2023 was $82.37M with 15.64% year-over-year growth.
Revenue (ttm)
$314.71M
Revenue Growth
+11.26%
P/S Ratio
15.86
Revenue / Employee
$346,980
Employees
907
Market Cap
4.99B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
Dec 31, 2018 | 181.28M | 22.02M | 13.83% |
Dec 31, 2017 | 159.25M | 44.86M | 39.21% |
Dec 31, 2016 | 114.40M | 42.70M | 59.55% |
Dec 31, 2015 | 71.70M | 26.11M | 57.28% |
Dec 31, 2014 | 45.59M | 24.64M | 117.64% |
Dec 31, 2013 | 20.95M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.32B |
Organon & Co. | 6.26B |
Option Care Health | 4.43B |
Bausch + Lomb | 4.15B |
R1 RCM | 2.25B |
Halozyme Therapeutics | 829.25M |
CRISPR Therapeutics AG | 371.21M |
Blueprint Medicines | 249.38M |
GKOS News
- 10 days ago - Glaukos Announces the Release of its 2023 Sustainability Report - Business Wire
- 17 days ago - Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1 - Business Wire
- 24 days ago - Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant) - Business Wire
- 26 days ago - Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting - Business Wire
- 2 months ago - Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 3 months ago - Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21 - Business Wire
- 3 months ago - Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance - Business Wire
- 4 months ago - Glaukos Announces Participation in the J.P. Morgan Healthcare Conference - Business Wire